Abstract Objectives This bibliometric study aimed to elucidate key developments, influential publications, and emerging research hotspots on
Abstract Objectives This bibliometric study aimed to elucidate key developments, influential publications, and emerging research hotspots on programmed cell death (PCD) in liver cancer–associated pain, thereby providing guidance for future mechanism-based, patient-centered therapies. Methods A comprehensive search was performed in the Web of Science using terms encompassing liver cancer, pain, and various PCD modalities. After multi-stage screening for relevance and quality, a dataset of 324 articles (2000–2024) was analyzed. Tools such as VOSviewer and Bibliometrix facilitated performance analysis, co-citation mapping, keyword clustering, and trend topic identification. Results The annual publication output increased notably after 2015, reflecting intensified interest in molecular pathways (apoptosis, ferroptosis, autophagy) and their clinical implications. China led in publication volume, while the USA and several European countries demonstrated high impact and extensive international collaborations. Keyword analysis revealed five thematic clusters, highlighting the prominence of inflammation, NF-κB signaling, oxidative stress–mediated apoptosis, combined therapeutic approaches, and metastasis-driven pain. Highly cited articles focused on flavonoids in apoptosis, immunogenic cell death, and cyclooxygenase-2 regulation, underscoring a shift toward integrative regimens that target both tumor progression and pain mechanisms. Conclusion Programmed cell death research in liver cancer pain has evolved into a rapidly expanding, multidisciplinary field. Findings point to a paradigm shift from purely cytotoxic strategies to more holistic approaches that merge immunotherapy, biomarker-driven diagnosis, and targeted interventions aimed at alleviating pain while controlling tumor growth. These insights lay the groundwork for precision-oriented, mechanism-based treatments that address the multifaceted challenges faced by patients with advanced liver cancer.
